培美曲塞二钠联合顺铂治疗晚期非小细胞肺癌的临床观察  

Clinical observation of pemetrexed combined with cisplaton in the treatment for advanced NSCLC

作　　者：贾晓琼[1] 刘利[1] 高德荣[1] 

机构地区：[1]内蒙古医学院附属人民医院肿瘤内科,内蒙古呼和浩特010020

出　　处：《现代肿瘤医学》2012年第10期2070-2072,共3页Journal of Modern Oncology

摘　　要：目的:探讨培美曲塞联合顺铂治疗晚期复发性非小细胞肺癌(NSCLC)的疗效以及不良反应。方法:经病理学或细胞学确诊的复发性晚期NSCLC患者39例,其中男性29例,女性10例,中位年龄50岁,KPS评分>70。培美曲塞500mg/m2第1天+顺铂60mg/m2第1天静脉滴注,每3周重复;至少2周期以上可评价疗效及不良反应。结果:39例中无完全缓解病例,部分缓解8例,稳定22例,进展9例,疾病控制率77%(30/39)。中位生存期10个月。其中鳞癌6.9个月,腺癌13.4个月,其他9.7个月,非鳞癌优于鳞癌,差异有显著性(P<0.05)。不良反应主要是骨髓抑制、胃肠道反应。结论:培美曲塞联合顺铂治疗晚期复发NSCLC疗效确切,不良反应发生率低,耐受性较好。Objective：To evaluate the efficacy and side effects for pemetrexed combined with cisplatin in the treatment of advanced recurrent NSCLC.Methods： Thirty-nine patients with advanced NSCLC who had failed to previous chemotherapy were enrolled in this study and all of these patients had been confirmed with pathology or cytology.Among the 39 cases,29 cases were male and 10 were female,the median age was 50 years.KPS scale70.All patients received pemetrexed 500mg/m2 on day 1 and cisplatin 60mg/m2 on day 1 by intravenous infusion,with 21 days as one cycle.All patients who received two or more cycles could be evaluated.Results： There was no case with complete response.Eight cases had partial response,twenty-two had stable disease and nine cases had progressive disease.The disease control rate was 77%（30/39）.The median survival time was ten months and of which 6.9 months in squamous cell carcinoma,13.4 months in adenocarcinoma,9.7 months in the others,respectively.There was significant difference between squamous cell carcinoma and non-squamous cell carcinoma（P0.05）.The common adverse effects were bone marrow suppression and gastrointestinal response.Conclusion： Pemetrexed combined with cisplatin is effective and feasible for advanced recurrent NSCLC.

关 键 词：培美曲塞二钠 顺铂 晚期非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]